{"article_title": "Why Sandoz Appeal To High Court Is Important For Biosimilars", "article_keywords": ["appeal", "court", "federal", "decision", "biosimilars", "amgen", "high", "worley", "important", "writ", "york", "sandoz", "petition", "view"], "article_url": "http://www.law360.com/articles/760842/why-sandoz-appeal-to-high-court-is-important-for-biosimilars", "article_text": "Why Sandoz Appeal To High Court Is Important For Biosimilars\n\nLaw360, New York (February 22, 2016, 10:04 AM ET) -- Robert Colletti\n\n\n\nDaniel Worley As many expected, Sandoz Inc. filed a petition for a writ of certiorari asking the U.S. Supreme Court to review the Federal Circuit\u2019s decision in Amgen Inc. v. Sandoz Inc.[1],[2] Amgen will have an opportunity to not only oppose Sandoz\u2019s petition but also to file a conditional cross petition.[3] Amgen is the first Federal Circuit decision to substantively interpret the Biologics Price Competition and Innovation Act of 2009, so whether the court decides to hear the case will be closely monitored by...\n\nTo view the full article, register now.", "article_metadata": {"description": "Amgen v. Sandoz is the first Federal Circuit decision to substantively interpret the Biologics Price Competition and Innovation Act of 2009, so whether the U.S. Supreme Court decides to hear the case will have a significant economic impact on both reference product sponsors and biosimilar applicants, as well as the general public, say Robert Colletti and Daniel Worley of Frommer Lawrence & Haug LLP.", "apple-itunes-app": "app-id=934560389, app-argument=law360://www.law360.com/articles/760842/why-sandoz-appeal-to-high-court-is-important-for-biosimilars", "csrf-token": "vziaFQ1D1vJmNRfzWti6L+U9JI/3tbNA2Whdo3sWG8E7x5WSXx2dc99ulkUVgR3vUWAIoASUALPwbqJp5Gjs0Q==", "csrf-param": "authenticity_token", "og": {"url": "http://www.law360.com/articles/760842/why-sandoz-appeal-to-high-court-is-important-for-biosimilars", "image": "https://www.law360.com/images/360.png", "type": "website", "title": "Why Sandoz Appeal To High Court Is Important For Biosimilars - Law360"}, "viewport": "width=device-width, initial-scale=1.0"}, "article_summary": "Why Sandoz Appeal To High Court Is Important For BiosimilarsLaw360, New York (February 22, 2016, 10:04 AM ET) -- Robert CollettiDaniel Worley As many expected, Sandoz Inc. filed a petition for a writ of certiorari asking the U.S. Supreme Court to review the Federal Circuit\u2019s decision in Amgen Inc. v. Sandoz Inc.[1],[2] Amgen will have an opportunity to not only oppose Sandoz\u2019s petition but also to file a conditional cross petition.\n[3] Amgen is the first Federal Circuit decision to substantively interpret the Biologics Price Competition and Innovation Act of 2009, so whether the court decides to hear the case will be closely monitored by...To view the full article, register now."}